Cas:32539-16-5 2-methylsulfanyl-5-(trifluoromethyl)-1,3,4-thiadiazole manufacturer & supplier

We serve Chemical Name:2-methylsulfanyl-5-(trifluoromethyl)-1,3,4-thiadiazole CAS:32539-16-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-methylsulfanyl-5-(trifluoromethyl)-1,3,4-thiadiazole

Chemical Name:2-methylsulfanyl-5-(trifluoromethyl)-1,3,4-thiadiazole
CAS.NO:32539-16-5
Synonyms:2-(Methylthio)-5-(trifluoromethyl)-1,3,4-thiadiazole;5-methylthio-2-(trifluoromethyl)-1,3,4-thiadiazole
Molecular Formula:C4H3F3N2S2
Molecular Weight:200.20500
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:196.733ºC at 760 mmHg
Density:1.559g/cm3
Index of Refraction:1.506
PSA:79.32000
Exact Mass:199.96900
LogP:2.27880

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-(Methylthio)-5-(trifluoromethyl)-1,3,4-thiadiazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-methylthio-2-(trifluoromethyl)-1,3,4-thiadiazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-methylthio-2-(trifluoromethyl)-1,3,4-thiadiazole Use and application,5-methylthio-2-(trifluoromethyl)-1,3,4-thiadiazole technical grade,usp/ep/jp grade.


Related News: There are limited treatment options for the disorder. Women with advanced endometrial cancer who are not candidates for curative therapy have a survival rate of just 17% 4,4′-(3-ethyl-4-(4-(2-(piperidin-1-yl)ethoxy)phenyl)furan-2,5-diyl)diphenol manufacturers “From the new company, we’ll be able to provide customers with invaluable access to high-quality sterile fill and finish capacity, which is in huge demand globally,” Recipharm CEO Marc Funk said in a release. tert-butyl ((4-(2-aminothiazol-4-yl)phenyl)carbamoyl)-L-phenylalaninate suppliers CHMP also recommended for approval Sanofi and Genzyme’s new Pompe disease drug, known in Europe as Nexviadyme (avalglucosidase alfa). Pompe disease is a rare, inherited disorder caused by the buildup of glycogen in the body’s cells. 1-(6-hydroxy-1-(1-oxo-14-pentaoxidaneyl)-1H-13,24,33,44,53,64,73,83,94-pentaoxolo[5,1]hexaoxin-2-yl)-24-hexaoxidan-2-one vendor & factory.